Company intelligence / Profile preview

Volition Veterinary Diagnostics

Belgium

Ownership: Private
Development stage: Other

Overview

The Nu.Q Vet Cancer Test has achieved 100% specificity and detects 74% of lymphomas and 89% of hemangiosarcomas in dogs. The test is the number one canine cancer screening blood test worldwide, available in over 20 countries with more than 100,000 tests sold in 2024. A point-of-care version is now available through Heska's Element i+ analyzer at under $50 per test.

Therapeutic areas: OncologyImmunology
Modalities: Blood-based diagnostic test (ELISA-based screening)
Industry: Veterinary

Partnerships

Heska Corporation (exclusive global supply and license agreement worth $28 million for worldwide distribution)Texas A&M University College of Veterinary Medicine & Biomedical SciencesBioguard (partnership for canine cancer screening in Taiwan)

Beyond the preview

Go deeper on Volition Veterinary Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Volition Veterinary Diagnostics.

Explore the full profile